(Q37643987)

21 August 2017

1 reference

title

Clinical management of uterine sarcomas (English)

1 reference

21 August 2017

3

Maria Debiec-Rychter

1 reference

21 August 2017

5

Ignace Vergote

1 reference

21 August 2017

4

Dirk Timmerman

1 reference

21 August 2017

1

Frédéric Amant

1 reference

21 August 2017

An Coosemans

2

1 reference

21 August 2017

1 December 2009

1 reference

Lancet Oncology Commission

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

12

1 reference

21 August 2017

1188-1198

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

21 August 2017

1 reference

7 January 2021

Imaging in gynecology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Uterine sarcoma: diagnosis with multiparameter sonographic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

MR imaging of uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Diffusely enlarged uterus: evaluation with MR imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

The management of patients with uterine sarcoma: a debated clinical challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

A gene expression signature associated with metastatic outcome in human leiomyosarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Genetic aberrations in soft tissue leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Array comparative genomic hybridization analysis of uterine leiomyosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Molecular characterisation of soft tissue tumours: a gene expression study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Differential gene expression in leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

PDGFR-alpha as a potential therapeutic target in uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Low-grade endometrial stromal sarcoma: hormonal aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Expression of androgen receptors in benign and malignant endometrial stromal neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

ERBB-2 gene overexpression and amplification in uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Tenets of PTEN tumor suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Immunohistochemical detection of WT1 protein in a variety of cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Imatinib is not a potential alternative treatment for uterine leiomyosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

ACOG committee opinion. No. 336: Tamoxifen and uterine cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

The classification of a uterine sarcoma as 'high-grade endometrial stromal sarcoma' should be abandoned

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

The diagnostic problem of endometrial stromal sarcoma: report on six cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Ultrasound findings in uterine mixed müllerian sarcomas and endometrial stromal sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

MR imaging of endometrial stromal sarcoma: correlation with pathologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

MR imaging findings of uterine endometrial stromal sarcoma: differentiation from endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Endometrial stromal sarcoma: a population-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Endometrial stromal sarcoma: treatment and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Lymph node metastases in low-grade endometrial stromal sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Endometrial Stromal Sarcoma: Analysis of Treatment Failures and Survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Ovarian preservation in stage I low-grade endometrial stromal sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Transition of endometrial stromal sarcoma into high-grade sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of c-KIT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Uterine gastrointestinal stromal tumour (GIST)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970226-8

7 January 2021

10.1016/S1470-2045(09)70226-8

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19959075